The 8-K says Lisata acquired Marea Therapeutics and issued 1,793,129 common shares plus 211,365.213 shares of Series C non-voting convertible preferred stock. Each preferred share is convertible into 1,000 common shares, subject to stockholder approval of the conversion proposal.

The risk is buried in the merger consideration: approval would turn the preferred into more than 211 million common shares before considering the separate common issuance. This is a dilution event first and an acquisition story second.

The filing discloses 2.875% exchangeable senior notes due 2031 and states that up to 24,999,988 shares of common stock may initially be issued upon exchange. The initial maximum exchange rate is 108.6956 shares per $1,000 principal amount of notes.

The risk sits in Item 3.02, where the potential share issuance is easy to miss behind the debt mechanics. For an office REIT, exchangeable paper adds dilution risk on top of balance-sheet sensitivity.

The filing says Bank7 entered a merger agreement with Century in lieu of a prior stock purchase transaction with the Receiver, while reserving rights under that purchase agreement if the merger fails. Consideration totals $70,000,000 in cash plus 1,232,657 Bank7 common shares, equal to $210.41 cash and 3.7052 Bank7 shares per Century share based on shares outstanding at signing.

The structure introduces execution and integration risk, especially because the filing explicitly preserves a fallback path if the merger does not close. Watch capital treatment, bank-level approvals, and whether the deal economics change before closing.

Amerant entered an underwriting agreement with Raymond James for $50 million aggregate principal amount of 7.00% senior notes due 2031 and completed the offering on September 17, 2026. The notes are unsecured and unsubordinated, with interest payable semi-annually beginning March 17, 2027.

The coupon is the tell: a regional bank raising five-year senior debt at 7.00% is paying real money for balance-sheet flexibility. The market should watch whether proceeds are defensive liquidity, growth capital, or refinancing pressure.

The filing says Verizon Master Trust and Cellco Partnership d/b/a Verizon Wireless entered an underwriting agreement for Series 2026-3 notes. The trust expects to issue $826,008,000 of Class A-1a notes, $65,000,000 of Class A-1b notes, $68,120,000 of Class B notes, and $40,872,000 of Class C notes on or about September 22, 2026.

This is not an equity dilution event, but it is a large funding-market signal tied to Verizon Wireless receivables. The risk is credit-market sensitivity: pricing and demand for consumer-payment ABS can reveal stress before it shows up in headline telecom results.